Prostamax (KEDP Tetrapeptide): Complete Research Profile — Khavinson Prostate Bioregulator (2026)

Prostamax (KEDP Tetrapeptide): Complete Research Profile — Khavinson Prostate Bioregulator (2026)

Prostamax is a synthetic tetrapeptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, targeting prostate gland tissue. With the amino acid sequence Lys-Glu-Asp-Pro (KEDP), it belongs to the KE-family of Khavinson bioregulatory peptides and is proposed to modulate prostate cell gene expression through the epigenetic chromatin decondensation mechanism characteristic of the entire bioregulator class.

The prostate gland is one of the organs most commonly affected by age-related pathology in males (benign prostatic hyperplasia, prostate cancer), making Prostamax research a topic of significant biological relevance in aging and men's health research contexts.

> Disclaimer: This article is for educational and research purposes only. Prostamax is not approved by the FDA or equivalent agencies for therapeutic use. Nothing herein constitutes medical advice.

---

Quick Reference

---

What Is Prostamax?

Prostamax is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Pro (one-letter code: KEDP), systematically named H-Lys-Glu-Asp-Pro-OH. The Pro (proline) residue at the C-terminus distinguishes it from other KED-family tetrapeptides:

• •Vesugen (KED): Vascular endothelium
• •Livagen (KEDA): Liver/chromatin
• •Testagen (KEDG): Testicular tissue
• •Prostamax (KEDP): Prostate gland

Prostamax has a confirmed PubChem CID: 9848296, where it is listed under synonyms including H-KEDP-OH and SCHEMBL6660498.

The Proline C-Terminal Residue

Prostamax's proline (Pro) C-terminal residue is notable because proline introduces a rigid kink in peptide chains due to its cyclic pyrrolidine ring structure. Unlike the flexible glycine (Testagen/KEDG) or the beta-methyl alanine (Livagen/KEDA), proline's conformational rigidity may influence the three-dimensional structure of the KEDP tetrapeptide and thereby its DNA-binding geometry and prostate-tissue specificity.

The pyrrolidine ring of proline:

• •Constrains backbone dihedral angles (φ angle limited to ~-60°)
• •Creates a characteristic "kink" at proline positions in peptide chains
• •Prevents standard α-helix and β-sheet formation at the proline site
• •This unique constraint may generate a specific binding conformation for prostate-expressed promoters

---

The Khavinson Bioregulator Framework

The Research Program

The Khavinson bioregulator program, ongoing since the 1970s at the Institute of Bioregulation and Gerontology in St. Petersburg, Russia, has systematically developed tissue-specific short peptides (2–5 amino acids) for each major organ system. The program's hypothesis is that peptides derived from or homologous to tissue-specific proteins can "reset" age-related epigenetic silencing in target tissues through direct DNA binding.

The full KE-family bioregulators derived from this program:

The KE core appears across multiple peptides with different C-terminal extensions that confer tissue specificity. This suggests the KE dipeptide provides a general chromatin-interacting scaffold, with the additional residues directing specificity to different target gene promoters.

Proposed Mechanism: Chromatin Decondensation

The Khavinson group's proposed mechanism for Prostamax (and all Khavinson bioregulators) involves:

1. Nuclear entry: Small molecular weight (<500 Da) allows passive diffusion through nuclear pore complexes

2. DNA binding: The KEDP sequence forms hydrogen bonds and electrostatic interactions with DNA bases and phosphate backbone in target gene promoters

3. Chromatin opening: Peptide binding displaces or loosens histone tail contacts with DNA, reducing nucleosome compaction

4. Gene expression: Target genes — particularly those encoding prostate-specific proteins and cellular maintenance functions — become more transcriptionally accessible

5. Tissue homeostasis restoration: Net effect is restoration of youthful gene expression profiles in aged prostate tissue

Molecular modeling studies published by the Khavinson group support DNA binding as mechanistically feasible for KEDP-length peptides. However, this mechanism remains debated in mainstream Western pharmacology literature, where sequence-specific DNA binding by very short peptides is considered unusual compared to transcription factors (which are far larger and employ specialized DNA-binding domains).

---

Prostate Gland Biology: The Research Context

Prostate Anatomy and Cell Types

The prostate gland is a walnut-sized glandular organ in males, located below the bladder and surrounding the urethra. Its primary physiological functions are:

• •Seminal fluid production: The prostate secretes components of seminal fluid including zinc, citric acid, proteolytic enzymes (PSA/kallikrein-3), and prostate-specific phosphatase
• •Ejaculatory coordination: Prostate smooth muscle contracts during ejaculation to project seminal fluid

The prostate consists of several zones and cell types:

• •Luminal epithelial cells: Secretory cells lining the glandular lumens; express high levels of androgen receptor (AR); secrete PSA and other products; primary cell type for prostate cancer initiation
• •Basal epithelial cells: Stem/progenitor-like cells underlying the luminal layer; low AR expression; thought to serve as cell of origin for some prostate cancers
• •Neuroendocrine cells: Rare cell type with paracrine regulatory functions; become important in castration-resistant prostate cancer
• •Stromal cells: Fibroblasts and smooth muscle cells; bidirectional signaling with epithelium through paracrine factors

Age-Related Prostate Changes

The prostate undergoes characteristic age-related changes that make it one of the most clinically significant organs in aging medicine:

Benign Prostatic Hyperplasia (BPH):

• •Affects 50% of men by age 60 and 90%+ by age 85
• •Involves non-malignant hyperplastic growth predominantly of the transition zone
• •Driven by hormonal shifts (relative estrogen increase, androgen receptor sensitivity changes), stromal-epithelial signaling dysregulation, and chronic inflammation
• •Causes lower urinary tract symptoms (LUTS): urgency, frequency, weak stream, nocturia
• •Current treatments: alpha-blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, surgical TURP

Prostate Cancer (PCa):

• •Most common cancer in men in the US and Europe
• •Predominantly affects men over 65; lifetime risk ~12%
• •Arises from luminal epithelial cells in the peripheral zone
• •Risk factors: age, heredity, race (highest in African-American men), obesity
• •Treatment landscape: active surveillance, radical prostatectomy, radiation, hormonal therapy (ADT), PARP inhibitors (for BRCA2+ cases), immunotherapy (Sipuleucel-T), chemotherapy

Epigenetic Aging in Prostate:

• •Increased DNA methylation at CpG islands of tumor suppressor genes (GSTP1, CDKN2A, RB1) begins in normal aging prostate before cancer development
• •Global histone methylation patterns shift with age
• •Reduced expression of differentiation genes; increased expression of inflammatory and proliferation pathways
• •These epigenetic changes are the direct target of Khavinson's proposed mechanism

---

Preclinical Research: Reported Findings

Prostate Epithelial Cell Studies

The Khavinson group's published Prostamax research focuses on the following endpoints in prostate cell culture and animal models:

Prostate cell proliferation and differentiation:

• •Prostamax treatment in aged rat prostate cell preparations restored proliferative markers toward young adult levels
• •Ki67 and PCNA (proliferating cell nuclear antigen) positive cells increased following Prostamax exposure in aged prostate epithelial cultures
• •Interpretation: Prostamax stimulates the regenerative capacity of aged prostate epithelium, which declines with age

Gene expression markers:

• •PSA (prostate-specific antigen/KLK3): Prostamax is reported to modulate PSA expression in prostate epithelial cells, consistent with androgen-responsive gene activation in luminal epithelium
• •AR (androgen receptor): Expression levels reported as maintained or upregulated following Prostamax treatment in aged models
• •Ki67, PCNA: Proliferation markers elevated, consistent with pro-proliferative effects on prostate tissue

Anti-apoptotic effects:

• •Caspase-3 activity reduced in Prostamax-treated prostate cell preparations
• •Consistent with the general anti-apoptotic pattern seen across Khavinson bioregulators in their respective target tissues

Animal Model Studies

Khavinson group studies in aged male rodents report:

• •Histological improvements in prostate gland structure (reduced glandular atrophy, improved epithelial organization) following Prostamax treatment
• •Maintained prostate secretory function in aged animals
• •No tumorigenic effects — an important safety parameter given the proliferative effects reported

Important Limitation: Research Context

All published Prostamax research comes from the Khavinson group and associated Russian institutions. Independent Western laboratory replication with blinded outcomes, standardized animal models, and modern genomic endpoints (RNA-seq, ChIP-seq) has not been published. This is a critical caveat for researchers interpreting the literature.

---

Research Applications

Current Research Use Cases

1. Prostate aging biology: Studying age-related changes in prostate epithelial gene expression and the potential for epigenetic reversal

2. Khavinson mechanism validation: Using Prostamax alongside other KE-family peptides (Vilon, Vesugen, Testagen) to investigate the class-level DNA-binding/epigenetic hypothesis with modern tools

3. BPH model research: Testing effects on stromal-epithelial signaling in hyperplasia models (testosterone-induced BPH in rodents)

4. Androgen receptor biology: Prostamax's effects on AR expression provide a research angle into androgen signaling regulation in prostate tissue

5. Comparative aging studies: Prostamax as part of multi-organ Khavinson bioregulator panels studying tissue-specific epigenetic aging reversal

6. Anti-apoptotic mechanism: Characterizing caspase pathway modulation in prostate epithelium for cancer-adjacent research

Research Design Recommendations

In vitro models:

• •LNCaP cells: Androgen-sensitive human prostate cancer cell line; high AR expression; good model for AR-related endpoints
• •PC-3 cells: Androgen-insensitive; useful for comparing AR-dependent vs. -independent effects
• •RWPE-1: Non-malignant human prostate epithelial cell line; better model for normal prostate biology
• •Primary human prostate epithelial cells: Gold standard for translational studies

Recommended assays:

• •RT-qPCR: PSA/KLK3, AR, KLK2, NKX3.1, TMPRSS2 expression
• •Immunofluorescence: Ki67, PCNA (proliferation), Caspase-3/7 (apoptosis), AR nuclear localization
• •Western blot: AR protein, PSA
• •ATAC-seq or ChIP-seq: Test chromatin accessibility at target gene promoters (the direct test of Khavinson's mechanism)
• •RNA-seq: Unbiased transcriptome profiling before/after Prostamax treatment

---

Prostate Research Landscape (2024–2026)

Advances in Prostate Epigenetics

The 2020–2026 period has seen major advances in prostate epigenomics directly relevant to Prostamax's proposed mechanism:

ATAC-seq and chromatin accessibility in prostate cancer progression:

• •Genome-wide chromatin accessibility maps of normal vs. BPH vs. localized PCa vs. metastatic PCa reveal progressive chromatin remodeling
• •Open chromatin regions in normal prostate are enriched for AR binding sites; cancer progression involves gain of new accessible regions at oncogenic regulatory elements
• •This ATAC-seq data provides the ideal substrate for testing whether Prostamax alters chromatin accessibility at prostate-specific gene loci

DNA methylation clocks in prostate:

• •The Horvath and Blackburn epigenetic clocks have been adapted for prostate tissue; prostate epigenetic age accelerates with cancer risk
• •GSTP1 promoter methylation in normal aging prostate is the best-validated epigenetic precancer marker
• •If Prostamax reverses epigenetic aging in prostate, GSTP1 methylation status would be a tractable biomarker

Androgen receptor signaling complexity:

• •New understanding of AR splice variants (especially AR-V7) in castration-resistant prostate cancer
• •AR coactivator/corepressor complexes (SRC-1/2/3, NCoR, SMRT) regulate AR target gene expression — potential interaction points for Prostamax
• •AR-dependent chromatin remodeling (SWI/SNF complex) is directly relevant to any chromatin-based mechanism

BPH Research Pipeline

BPH remains a high-prevalence, poorly-served condition for disease modification:

• •Current drugs (tamsulosin, finasteride) treat symptoms but don't address underlying stromal-epithelial dysregulation
• •Serenoa repens (saw palmetto) — the most studied natural BPH agent — has mixed clinical evidence; Cochrane review 2012 showed no benefit over placebo
• •New research directions include: PI3K pathway inhibitors, mTOR inhibitors, senolytic approaches to clear senescent stromal cells
• •Prostamax's proposed anti-proliferative (in the context of normalizing hyperproliferation) and pro-differentiation effects in prostate epithelium could theoretically address BPH biology if its mechanism is confirmed

---

Comparison to Other Prostate Health Research Compounds

Prostamax occupies a distinctive research niche: if the proposed epigenetic mechanism is validated, it offers potential prostate tissue homeostasis restoration through a mechanism entirely orthogonal to androgen signaling, which dominates the current prostate drug landscape.

---

Prostamax Pricing: Research Supplier Landscape (2026)

Prostamax is available from multiple research peptide suppliers. As a tetrapeptide of moderate complexity, synthesis is straightforward and prices are generally accessible:

View live pricing and verified supplier details at Peptides.SO. Prices reflect current listings.

Quality verification checklist for research-grade Prostamax:

• •HPLC purity ≥95% with single-peak chromatogram
• •Mass spectrometry confirming [M+H]+ at ~488.5 Da
• •Correct sequence verification (KEDP not KEPD or KDEP)
• •Lot-specific Certificate of Analysis
• •Sterility and endotoxin testing if used in animal studies

---

Reconstitution and Handling

Reconstitution Protocol

• •Dissolve lyophilized powder in sterile PBS, 0.9% saline, or bacteriostatic water
• •Target working concentration: 100 µg/mL for standard applications
• •Gently swirl — avoid vortexing of small volumes
• •Filter through 0.22 µm syringe filter for sterile in vivo applications

Cell Culture Protocol

• •Add Prostamax to culture medium at 10–1,000 ng/mL (based on Khavinson published range)
• •Typical treatment duration: 24h for gene expression; 7–14 days for proliferation/morphology
• •Include vehicle control (PBS at equivalent volume) and positive control (e.g., DHT for AR endpoints)

Storage Recommendations

• •Lyophilized: -20°C, desiccated; stable ≥2 years
• •Aqueous solution (reconstituted): -20°C for long-term; 4°C for short-term (<1 week)
• •Avoid >3 freeze-thaw cycles
• •No special container requirements; standard polypropylene microcentrifuge tubes adequate

---

The KE-Family: Understanding Prostamax's Place in the Lineage

Prostamax's relationship to the broader KE-family peptides provides useful context for research design:

KE (Vilon): The core dipeptide; thymus-targeting; studied extensively for immune restoration in aged animals. The KE sequence provides the basic chromatin-interacting scaffold.

KED (Vesugen): Adds Asp to KE; shifts targeting to vascular endothelium. The additional negative charge from Asp may alter the DNA-binding geometry to favor vascular gene promoters.

KEDA (Livagen): Adds Ala to KED; liver targeting and chromatin decondensation effects in hepatocytes. Alanine's neutral, small side chain doesn't significantly alter charge but may affect steric fit.

KEDG (Testagen): Adds Gly to KED; testicular targeting; testosterone-related effects reported. Glycine provides maximal conformational flexibility at the C-terminus.

KEDP (Prostamax): Adds Pro to KED; prostate targeting. Proline's ring structure creates conformational rigidity — the most conformationally constrained of the KED variants.

The pattern suggests that the KE core provides basic DNA binding capacity, while the C-terminal residue (A, G, P, etc.) acts as a "selector" that directs the peptide to tissue-specific promoters through distinct conformational or chemical interactions.

---

Critical Assessment: What Researchers Should Know

Strengths of the Prostamax Literature

1. Reproducible within the Khavinson program: Effects have been consistently reported across multiple publications from the Institute

2. Mechanistically coherent: The proposed epigenetic mechanism is internally consistent across the entire bioregulator class

3. Clear biomarker endpoints: Studies report specific molecular markers (Ki67, Caspase-3, PSA, AR) that are measurable with standard tools

4. Absence of reported toxicity: No significant adverse effects in preclinical studies

5. Commercially available: Multiple suppliers offer Prostamax at accessible research prices

Limitations and Gaps

1. Single research group: All primary data originates from the Khavinson Institute; independent replication is absent in Western literature

2. Mechanism unproven by Western standards: Direct DNA-binding evidence using modern chromatin tools (ChIP, ATAC-seq) has not been published

3. No human clinical trials: Unlike GLP-1 agonists or even less-studied peptides like BPC-157, Prostamax has no published human safety or efficacy data

4. Limited mechanistic depth: Most publications report endpoint data (proliferation, apoptosis markers) without dissecting the signaling pathway between KEDP exposure and observed effects

5. Species translation: Rodent prostate anatomy and cancer biology differ significantly from human; NHP data does not exist for Prostamax

Value for Independent Research

Despite these limitations, Prostamax has genuine value for independent researchers:

• •As a mechanistic tool to test Khavinson's epigenetic hypothesis with modern genomics approaches
• •As part of comparative KE-family studies examining structure-activity relationships
• •As a starting point for prostate-targeted epigenetic research using KEDP as a scaffold for optimized analogs

---

Frequently Asked Questions

Q: What is the difference between Prostamax and Testagen?

A: Both belong to the KED family but differ in their C-terminal residues: Testagen is KEDG (glycine C-terminus, flexible) targeting testicular tissue; Prostamax is KEDP (proline C-terminus, rigid) targeting prostate tissue. Their tissue specificities differ despite the shared KED core — consistent with the Khavinson hypothesis that C-terminal residues direct tissue specificity.

Q: Could Prostamax promote prostate cancer growth?

A: This is an important safety consideration. Prostamax's reported pro-proliferative effects on prostate epithelium raise theoretical concern. However, Khavinson studies report no tumorigenic outcomes in animal models. The proposed mechanism involves restoration of normal differentiated gene expression rather than oncogenic transformation. That said: researchers should use standard safety controls (tumor model experiments, proliferation in cancer cell lines) and not use Prostamax in animal models with existing prostate tumors without appropriate precautions.

Q: Is Prostamax used as a supplement outside research contexts?

A: Khavinson bioregulators including a "Prostamax" branded product have been commercially distributed as dietary supplements in Russia and some European markets. This is distinct from research use and does not validate safety or efficacy for therapeutic use in Western regulatory contexts.

Q: How does Prostamax relate to PSA testing?

A: Some Prostamax research reports effects on PSA expression. Since PSA (KLK3) is primarily an androgen-responsive gene expressed in luminal prostate epithelium, PSA modulation is consistent with effects on androgen-responsive gene expression in prostate tissue. Researchers using PSA as an endpoint should note that it is a non-specific marker reflecting prostate epithelial activity broadly, not cancer-specific.

Q: What is the recommended study design for a first Prostamax experiment?

A: For an initial characterization study, use primary human prostate epithelial cells or RWPE-1 cells. Treat with a dose-response series (1, 10, 100, 1000 ng/mL) for 24h and 72h. Measure: cell viability (MTT), proliferation (Ki67 IF), apoptosis (Caspase-3/7 activity), and gene expression (RT-qPCR for PSA, AR, NKX3.1, KI67). Include DHT-stimulated positive control and vehicle (PBS) negative control. This design will generate a dose-response profile and establish whether Prostamax has reproducible effects in your cell system.

---

Related Research Articles

• •Cartalax: Complete Research Profile — Khavinson Bioregulator for Cartilage
• •Vesugen (KED Tripeptide): Complete Research Profile — Vascular Endothelium Bioregulator
• •Testagen (KEDG Tetrapeptide): Complete Research Profile — Testicular Bioregulator
• •Peptide Purity Testing Methods: HPLC and Mass Spectrometry Explained
• •How to Reconstitute Peptides: Ultimate Guide

---

Conclusion

Prostamax (KEDP) occupies a distinctive position in the prostate research landscape: a tissue-targeted epigenetic modulator with a mechanistically coherent hypothesis derived from 50+ years of systematic Khavinson bioregulator research, but awaiting independent validation with modern molecular tools.

The prostate's clinical significance — as the most common site of cancer in men and the nearly universal target of benign hyperplasia with aging — makes any well-characterized prostate-targeted research compound worth serious scientific attention. If Prostamax's proposed chromatin decondensation mechanism is validated by independent research using ATAC-seq, ChIP-seq, and transcriptomic approaches, it would represent a fundamentally new class of prostate-targeted intervention: one acting at the gene expression level rather than through androgen receptor modulation.

For researchers in prostate biology, epigenetics, or aging medicine, Prostamax offers a tractable experimental compound with clear published biomarker endpoints, accessible commercial availability, and a specific testable mechanism. The next important step is independent Western validation — which represents both the primary uncertainty and the primary research opportunity.

Research Use Only. Prostamax (KEDP) is sold for research purposes only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Consult applicable regulations before use.